Rifamycin Derivatives Are Effective Against Staphylococcal Biofilms In Vitro and Elutable From PMMA
Abstract
Local antimicrobial delivery through poly-methylmethacrylate beads (PMMA), commonly vancomycin, is used for the treatment of contaminated open fractures but has limited activity against Staphylo- coccus aureus biofilms, which occur commonly in such fractures. Rifamycins have activity against biofilms and are an effective treatment for osteoarticular infections involving staphylococcal biofilms, but there are limited studies evaluating the activity of rifamycin derivatives, other than rifampin, against biofilms of S. aureus and evaluating incorporation of these drugs into PMMA for treatment of contaminated open fractures. Questions/purposes (1) Are rifamycin derivatives effective against established biofilms of clinical isolates of S. aureus ? (2) Can PMMA be used as a carrier for rifamycin derivatives? Biofilms were developed and evaluated for susceptibility to a panel of antimicrobials in vitro using the minimum biofilm eradication concentration high-through- put model. Susceptibility was assessed by measuring bacterial recovery at 6 and 24 hours after antimicrobial treatment. Activity of rifamycin derivatives against intra- cellular bacteria was also evaluated using a gentamicin protection assay. Evaluation of PMMA as a carrier for rifampin and rifamycin derivatives was determined by assessing the curing time subsequent to loading of rifamycins and characterizing the release kinetics of rifamycins at daily intervals for 14 days from PMMA by performing bioassays.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 21, 2015
- Accession Number
- ADA620463
Entities
People
- Carlos J. Sanchez Jr.
- Clinton K. Murray
- David J. Tennent
- Joseph C Wenke
- Sharanda K. Hardy
- Stefanie M Shiels
Organizations
- United States Army Institute of Surgical Research